Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib

A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed rechallenge with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hotta, Takamasa, Okimoto, Tamio, Hamaguchi, Megumi, Tsubata, Yukari, Isobe, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008039/
https://www.ncbi.nlm.nih.gov/pubmed/31534079
http://dx.doi.org/10.2169/internalmedicine.2597-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008039/
https://www.ncbi.nlm.nih.gov/pubmed/31534079
http://dx.doi.org/10.2169/internalmedicine.2597-18

Ejemplares similares